Pharma APMs: Can the industry learn to play well with others?

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Maggie Alston, Bruce S. Pyenson | 05 September 2018

Pharmaceutical manufacturers and insurers may embrace alternative payment models (APMs) as a payment mechanism in some situations. The dynamics of APMs suggest a potential win for insurers, pharmaceutical manufacturers, and patients through an emphasis on reducing cost and improving outcomes.

This article was originally published by Managed Care.

Read or print the article